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Background: To compare the results of radiofrequency ablation (RFA) with hepatic resection in the
treatment of hepatocellular carcinoma (HCC) within the Milan criteria.
Methods: A nonrandomized comparative study was performed with 111 consecutive patients who
underwent laparoscopic RFA (n ¼ 31) or curative hepatic resection (n ¼ 80) for HCC within Milan criteria.
Results: Procedure related complications were less often and severe after RFA than resection (3.2% vs.
25%). There was no signiﬁcant difference in hospital mortality (0% vs. 3.8%). Hospital stay was signiﬁ-
cantly shorter in the RFA group than in the resection group (mean, 3.8 vs. 6.8 days). The 1-, 3-, and 5-year
disease-free survival rates for the RFA group and the resection group were 76%, 40%, 40% and 76%, 60%,
60%, respectively. Disease-free survival was signiﬁcantly lower in the RFA group than in the resection
group. The corresponding 1-, 3-, and 5-year overall survival rates for the RFA group and the resection
group were 100%, 92%, 84%, and 92%, 75%, 71%, respectively. The overall survival for RFA and resection
were not signiﬁcantly different.
Conclusions: Our result showed comparable overall survival between RFA and surgery, although RFA was
associated with a signiﬁcantly higher tumor recurrence rate. RFA had the advantages over surgical
resection in being less invasive and having lower morbidity.
 2012 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Hepatocellular carcinoma (HCC) is a major health problem
worldwide, with an estimated incidence ranging between 500,000
and 1,000,000 new cases annually. It is the ﬁfth most common
cancer in the world, and the third most common cause of cancer-
related death.1,2 Each treatment modality for HCC can be consid-
ered to have one of three goals: cure, local control and bridge to
transplantation, and palliation. For years, partial hepatectomy and
liver transplantation have been considered as the main curative
treatments. Various locoregional therapies are used for patients
who are not candidates for surgical cure because of severity of liver
disease or advanced stage of HCC1e4.
In the past 2 decades, local ablative therapies, including
percutaneous ethanol injection (PEI), microwave coagulative
therapy (MCT) and radiofrequency ablation (RFA), have emerged to
be a safe and effective treatment in patients with small HCC
conﬁned to the liver, especially when the tumors are unresectable
due to poor general condition or because of compromised liverax: þ86 852 2515 3195.
. Lai).
ciates Ltd. Published by Elsevier Ltfunction. The application of local ablative therapy has a number of
potential advantages in high-risk patients with HCC. The procedure
is relatively safe and well tolerated and its complication rates in
most series have been low.5e8 Recently, there has been a drastic
shift of usage from PEI/MCT to RFA. Available evidence from
adequate quality controlled studies support the superiority of RFA
versus PEI/MCT, in terms of better survival and local control of the
disease, for the treatment of patients with relatively preserved liver
function and early-stage non-surgical HCC.9e14
Although partial hepatectomy and liver transplantation offer the
best chance of cure in patients with resectable tumor, recent
evidence suggested that RFA for small tumors may offer comparable
survival results. RFA has distinct advantages compared with surgical
resection of HCC. It is minimally invasive, and has much lower
morbidityandmortality rates than surgery. RFA is aversatile tool that
can be applied percutaneously, laparoscopically, or at open surgery.
Open and laparoscopic approaches have the potential advantages of
beingmoreprecise in staging thedisease, in treating larger tumors by
using the multiple probe or the multiple probe application tech-
niques, in treating lesions near to an adjacent organ by dissecting
away or by resecting the organ, in treating lesions inaccessible
percutaneously, and the use of intraoperative ultrasound to detect
additional tumors which are not seen by preoperative imaging.d. All rights reserved.
Table 1
Demographic and liver functional data.
Variables RFA (n ¼ 31) Liver resection
(n ¼ 80)
p-Value
Age (years) 63.1  12.8 60.8  9.9 0.33
Sex ratio (male/female) 19/12 55/25 0.26
HBsAg (n) 25 65 0.53
Mean tumor size (cm) 1.8  0.6 2.9  1.1 0.44
Patient with solitary tumor (n) 28 71 0.32
Liver cirrhosis (n) 24 62 0.91
Preoperative laboratory results 0.09
Bilirubin (umol/L) 13.7  7.4 11  6.5 0.61
Albumin (g/L) 38.2  4.1 38.7  4.4 0.40
Creatinine (umol/L) 82.7  14 87.2  28 0.89
Prothrombin time (sec) 10.9  1 11  2.2 0.11
Platelet count (109/L) 144.2  68.7 168  63.9 0.25
Hemoglobin (g/dL) 13.1  1.4 13.5  1.8







Variables RFA (n ¼ 31) Liver resection (n ¼ 80) p-Value
Mean operating
time (mins)
67.9  27.7 177.9  7.2 0.005
Mean blood loss 29.6 (range, 1e550) 511.5 (range, 5e3500) 0.005
Morbidity (n) 1 (3.2%) 20 (25%) 0.006
Mortality (n) 0 (0%) 3 (3.8%) 0.262
Mean post-operative
hospital stay (days)
3.8  1.7 6.8  4 0.00012
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tory. Therefore, we conducted this nonrandomized comparative
study to compare the results of RFA with hepatic resection in the
treatment of HCC within the Milan criteria.
2. Patients and methods
Between January 2006 and December 2012, 111 consecutive patients in a single
tertiary referral center underwent RFA therapy (n ¼ 31) or curative hepatic resection
(n¼ 80) forHCCswithin theMilan criteria: i.e., a solitaryHCCup to 5 cm indiameter, or
for no more than 3 tumor nodules each 3 cm or less in diameter. The preoperative
diagnosis of HCC was based on the diagnostic criteria for HCC used by the European
Association for the Study of the Liver. HCC was diagnosed by at least 2 radiologic
imaging showing characteristic features of HCC; or 1 radiologic imaging showing
characteristic features ofHCCassociatedwith alpha-fetoprotein (AFP)> 400 ng/mL; or
cytologic/histologic evidence. In general, patients were offered both options of treat-
ments. The potential advantages and disadvantages of both treatments were fully
explained, and the patientsmade the decision of treatment option. However, for those
centrally located tumor, our team preferred to offer RFA treatment. All procedures
were performed after obtaining informed consent. The procedure related parameters,
surgical outcome and survival were compared between the two groups of patients.
All patients had a chest X-ray, ultrasonography (USG) of abdomen and contrast
computed tomography (CT) scan of abdomen. A lipiodol-CT scan was performed in
selected patients. Laboratory blood tests including hepatitis B surface antigen,
antibodies to hepatitis C, serum AFP, serum albumin, serum total bilirubin, aspartate
aminotransferase, alanine aminotransferase and prothrombin time were obtained
and the Pugh’s modiﬁcation of Child’s criteria was determined. Further investiga-
tions were performed only when there was clinical suspicious of extrahepatic
metastases. Radiologic studies were reviewed in a multidisciplinary case manage-
ment meeting held weekly.
2.1. Procedure
In hepatic resection group, surgery was carried out under general anesthesia
using open approach, total laparoscopic approach, hand-assisted laparoscopic
approach or robot-assisted laparoscopic approach. We mainly selected those tumor
located at anterio-inferio-lateral segments (Couinaud segments 2, 3, 4b, 5, 6) for
laparoscopic resection.
In the RFA group, all the patients underwent laparoscopic RFA under real-time
ultrasonographic guidance in an operative room setting under general anesthesia.
Cool-tip (Covidien, Inc. Boulder, CO, USA) was utilized in all patients.
2.2. Follow-up
A three-phase spiral computed tomography (CT) was done 4 weeks after
treatment and thereafter every 3e6 monthly in the ﬁrst 2 years. At each of these
follow-up visits, blood tests including liver function tests and serum AFP were done.
Chest radiographywas done every 6months. The follow-up visits were spaced out to
once every 6 months after 2 years.
2.3. Statistical method
Continuous variables were expressed as median (range) or mean  standard
deviation (SD) and were compared using the student t test. Categorical variables
were compared using the c2 test. Overall survival and disease-free survival were
measured from the date of procedure to the time of death and to the time when
recurrent tumor was ﬁrst diagnosed, respectively. Survival analysis was estimated
by the KaplaneMeier survival method, and the differences in survival between the
groups were compared using the log-rank test. P-value less than 0.05 was consid-
ered statistically signiﬁcant.
3. Results
Of the 111 patients with HCC within Milan criteria included in
the analysis, 31 were treated by laparoscopic RFA and 80 were
treated by hepatic resection. In the RFA group, 2 patients needed
conversion to open RFA due to unfavorable position for laparo-
scopic RFA. In the hepatic resection group, open approach, total
laparoscopic approach, hand-assisted laparoscopic approach and
robot-assisted laparoscopic approach was used in 34, 10, 6 and 30
patients, respectively. Two patients in total laparoscopic and 2
patients in robot-assisted laparoscopic group needed open
conversion due to bleeding from venous branches. The preopera-
tive demographic and liver function data of these 2 groups of
patients are shown in Table 1. There is no signiﬁcant differencebetween these 2 groups of patients in the factors being analyzed.
The R0 resection rate was 97.4% in the resection group.
3.1. Treatment morbidity and mortality
RFA group had signiﬁcantly shorter procedure time (mean, 67.9
vs. 177.9 min) and less blood loss than resection group (mean, 29.6
vs. 511.5 ml). Procedure related complications were less often and
severe after RFA than resection (3.2% vs. 25%). There was no
signiﬁcant difference in hospital mortality (0% vs. 3.8%). Hospital
stay was signiﬁcantly shorter in the RFA group than in the resection
group (3.8  1.7 days vs. 6.8  4 days) (Table 2).
3.2. Recurrence and survival
Mean follow-up was 35.1  17.4 months for patients treated
with RFA and 29.7  19.9 months for resected patients.
In RFA group, tumor recurred in 16 patients (51.6%) (local
recurrence, n ¼ 15; distant metastasis, n ¼ 1). Among the 15
patients with local recurrence, HCC recurrence developed at the
site of the RFA in 5 and at a different intrahepatic site in 10 of these
patients. For these patients with HCC recurrences, they were
treated with partial hepatectomy (n ¼ 5), RFA (n ¼ 4), TACE (n ¼ 3),
combined RFA and TACE (n¼ 1), and combined TACE and conformal
radiotherapy (n ¼ 1). Three patients in the RFA group died during
the follow-up and all the causes of death were due to HCC
recurrence.
In resection group, tumor recurred in 21 patients (27.3%) (local
recurrence, n ¼ 20; distant metastasis, n ¼ 1). Among the 20
patients with local recurrence, HCC recurrence developed at the
site of the treated tumor in 3 and at a different intrahepatic site in
17 of these patients. For these patients with HCC recurrences, they
were treated with partial hepatectomy (n ¼ 3), RFA (n ¼ 4), TACE
(n ¼ 2), combined RFA and ethanol injection (n ¼ 1), combined RFA
and TACE (n ¼ 1), combined TACE and conformal radiotherapy
E.C.H. Lai, C.N. Tang / International Journal of Surgery 11 (2013) 77e80 79
ORIGINAL RESEARCH(n ¼ 1), and systemic target therapy (n ¼ 1). Twelve patients in the
resection group died during the follow-up and 6 deaths were due to
HCC recurrence.
The 1-, 3-, and 5-year disease-free survival rates for the RFA
group and the resection group were 76%, 40%, 40% and 76%, 60%,
60%, respectively. Disease-free survival was signiﬁcantly lower in
the RFA group than in the resection group (p ¼ 0.037). The corre-
sponding 1-, 3-, and 5-year overall survival rates for the RFA group
and the resection group were 100%, 92%, 84%, and 92%, 75%, 71%,
respectively. The overall survival for RFA and resection were not
signiﬁcantly different (p ¼ 0.166) (Figs. 1 and 2).Fig. 2. Overall survival curves (p ¼ 0.166).4. Discussion
For many years, partial hepatectomy and liver transplantation
have been considered as the main forms of curative treatment.
Recent evidence suggested that local ablative therapy for small
tumors may offer comparable survival results.15e18 PEI and hepatic
resection have shown comparable results for patients with small
tumors. Huang et al. published in 2005 the ﬁrst RCT comparing
resection and PEI in 76 patients with 1 or 2 tumors with diameter
3 cm.15 The 1-, and 5-year overall survival rates were 100%, and
46% for the PEI group and 97.4%, and 81.8% for the resection group,
respectively. The corresponding disease-free survival rates were
76.1%, and 44.6% for the PEI group and 89.5, and 48.2% for the
resection group, respectively. There was no signiﬁcant difference in
the overall and disease-free survivals between the 2 groups,
although there was a reported difference of 35.8% in the 5-year
overall survival rates. Recently, there has been a drastic shift of
usage from PEI to RFA. Five randomized comparative trials (RCTs)
showed that RFA is superior to PEI in the treatment of HCC in not
only tumor response but also long-term survival.10e14 Currently,
survival results with RFA have improved to such a point that RFA is
beginning to challenge hepatic resection as a ﬁrst line treatment for
HCC. Compared with hepatic resection, RFA has several potential
advantages. It is a low risk procedure with minimal mortality and
limited morbidity. It is cheaper than hepatic resection, widely
available, readily repeated. Amajor drawback of RFA is the high rate
of disease recurrence after treatment. This may have an adverse
effect on patient survival. Several cohort studies, and comparative
studies showed initial encouraging results. In the cohort study of
Livraghi et al., 218 patients with a single resectable HCC 2 cm
underwent RFA.16 Perioperative mortality, major complication, andFig. 1. Disease-free survival curves (p ¼ 0.037).5-year survival rates were 0%, 1.8%, and 68.5%, respectively. Chen
et al. conducted an RCT on 180 patients with a solitary HCC 5 cm
to receive either percutaneous RFA or surgical resection.17 This RCT
showed percutaneous RFA to give similar overall and disease-free
survivals as surgical resection for patients with solitary and small
HCC. The 1-, and 4-year overall survival rates after percutaneous
RFA and surgery were 95.8%, 67.9% and 93.3%, 64.0%, respectively.
The corresponding disease-free survival rates were 85.9%, 46.4%
and 86.6%, 51.6%, respectively. The authors concluded that percu-
taneous RFA had the advantage over liver resection in giving better
short term postoperative results because percutaneous RFA is a less
invasive procedure. The results from these and other non-
randomized studies have ledmany to consider RFA as an alternative
to resection in patients with small HCC. However, there is also an
RCT that showed surgical resection to be signiﬁcantly better in the
patients’ overall survival and disease-free survival when compared
with RFA. Recently, the RCT of Huang et al. compared the long-term
outcomes of surgical resection and RFA for the treatment of 230
HCC patients who met the Milan criteria.18 The 1-, 3-, and 5-year
overall survival rates for the RFA group and the resection group
were 86.96%, 69.57%, 54.78% and 98.26%, 92.17%, 75.65%, respec-
tively. The corresponding recurrence-free survival rates for the 2
groups were 81.74%, 46.08%, 28.69% and 85.22%, 60.87%, 51.30%,
respectively. Overall survival and recurrence-free survival were
signiﬁcantly lower in the RFA group than in the resection group.
Our study showed that hepatic resection offered better local
control of HCC with reduced local recurrence rates and longer
disease-free survival compared with RFA, but these advantages did
not translate into better overall survival. The explanation for this
lies with the higher early mortality of resection, death resulting
from underlying liver disease and the potential for new foci of HCC
to develop elsewhere in the cirrhotic liver remnant. Repeat
resection is rarely possible and even RFA can be more difﬁcult to
perform in patients after resection. With the preserved liver
functional remnant, tumor recurrence after RFA can generally be
re-treated with surgery or various modalities of local-regional
therapy, which may explain the comparable overall survival rates
between RFA and resection.19 Whether the higher recurrence rate
has any effect on overall well-being and health related quality of
life remains to be investigated. However, there were two limita-
tions of our study. Firstly, it was a nonrandomized comparative
study. There might be some bias in the treatment selection.
Furthermore, there was a great discrepancy of number of patients
in both arms.
E.C.H. Lai, C.N. Tang / International Journal of Surgery 11 (2013) 77e8080
ORIGINAL RESEARCHThe current literature favors minimally invasive liver resection
over open liver resection in terms of morbidity in selected
patients.20 We also noted similar trends of ﬁndings in our experi-
ence.We have previously analyzed themorbidity rate of 72 patients
with conventional and hand-assisted laparoscopic liver resection
and 32 patients with robot-assisted laparoscopic liver resection.21
The complication rates were 20.8%, and 9.4%, respectively. There
was no surgical mortality. However, the morbidity rate was still
higher than that of RFA group (3.2%) in the current study. The
morbidity and mortality rate in the current series of mixed lapa-
roscopic and open liver resection was 25% and 3.8%, respectively.
However, it was difﬁcult to compare between both groups of
patients because those selected patients for laparoscopic liver
resection had more favorable tumor locations and smaller tumor
sizes.
In conclusion, our result showed comparable overall survival
between RFA and surgery, although RFA was associated with
a signiﬁcantly higher tumor recurrence rate. RFA had the advan-
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